Medication info
Jardis Duo Tablet 12.5/850 mg (Empagliflozin, Metformin)

Jardis Duo Tablet 12.5/850 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink-tinged white, biconvex, oval-shaped film-coated tablet
Packaging
60 tablets/bottle [10 tablets/PTP x 6], 30 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle
Approval status
Active

MFDS item code 202302788 · Approved 2023.09.20 · Insurance code 657808070

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients 75 years of age or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Blood sugar control disorder
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to assist adults with type 2 diabetes in controlling blood sugar levels, complementing dietary and exercise regimens. It is particularly effective for those whose blood sugar is not adequately controlled, and can also be used in patients with confirmed cardiovascular disease. Caution should be observed according to the guidelines provided by a specialist when using this medication. It helps improve blood sugar levels and aids in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients 75 years of age or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is for the treatment of diabetes, with the active ingredients being empagliflozin and metformin. Severe lactic acidosis, a rare side effect, can occur when taking this medication and requires great caution. Lactic acidosis can lead to a hazardous condition from excessive lactic acid in the body, which can potentially be fatal. Additionally, when taken with other diabetes medications such as insulin or sulfonylureas, the risk of hypoglycemia should be noted. This medication should not be administered to patients with moderate to severe renal impairment, acute kidney issues, severe infections, heart failure, acute myocardial infarction, or other serious conditions. Furthermore, it is recommended that pregnant women, women who may become pregnant, and breastfeeding women avoid this medication for safety. Patients taking this medication should have regular kidney function and blood tests, with more frequent tests required for the elderly or patients with slightly reduced kidney function. Common side effects may include gastrointestinal disturbances, urinary tract infections, genital infections, increased urination, and hypoglycemia, and consultation with medical personnel is necessary if symptoms appear. Particularly during symptoms of dehydration, vomiting, or diarrhea, caution should be exercised due to the risk of fluid depletion, and in such cases, medication may be temporarily suspended. The use of this medication should be stopped for a period around surgery or imaging tests involving iodinated contrast and should not be resumed until kidney function is confirmed normal. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. This medication is not recommended for individuals under 18 years of age, as safety and efficacy have not been established in children. Elderly patients should be particularly careful as they have an increased risk of renal impairment and fluid loss. In cases of overdose, the risk of lactic acidosis exists, and immediate medical attention is necessary.

Storage

This medication should be kept in a tightly sealed container to avoid exposure to air or moisture. It is best to store it at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness.

Appearance and packaging

Appearance

Pink-tinged white, biconvex, oval-shaped film-coated tablet

Package unit

60 tablets/bottle [10 tablets/PTP x 6], 30 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.